By Ed Susman, Contributing Writer, MedPage Today
STOCKHOLM – In preliminary studies, women diagnosed with advanced ovarian cancer who received an autologous dendritic cell vaccine appear to achieve extended survival benefits, researchers reported here.
One-year survival was about 89% in patients who received a vaccine pulsed with lysate of tumor cells; and about 93% in the patients who received the cells pulsed with Bacillus subtilis B-7025 cytotoxic lectins (LTCCL), (P
Those figures compared with about 80% one-year survival in the control group Khranovska said at a poster presentation at the European Multidisciplinary Cancer Conference, formerly known as the Congress of the European Cancer Organization and Congress of the European Society for Medical Oncology.
Two-year survival was 20.5% in the control group, 47.8% among the lysate of tumor cell infused group and 53.1% of the LTCCL vaccine group (P
Three-year survival was 13.2% in the control group, 26.7% in the lysate of tumor cell group, and 39.8% of the patients receiving the LTCCL vaccine (P
“There was clear evidence of clinical benefit of vaccine therapy by dendritic cells pulsed with lysate of tumor cells with cytotoxic lectins for advanced ovarian cancer.” Khranovska said.
Another researcher exploring an autologous vaccine for ovarian cancer, Janne Kærns, MD, of Oslo University Radiumhospital in Oslo, Norway, told MedPage Today that the “Ukraine work is interesting but it is very early in the process.
“We have seen that vaccine approaches have been helpful in melanoma and prostate cancer, so it is possible it will be effective in advanced ovarian cancer as well. It is a developing field,” said Kærns.
Khranovska explained that her team embarked on the vaccine development based on previous studies. She said that many researchers have tried to enhance methods of loading dendritic cells with tumor antigens.